Co-development Deals in Pharmaceuticals and Biotechnology 2016-2026
Analyze co-development deals in pharma and biotech from 2016 to 2026. Includes financials, deal terms, and access to actual contracts where available.
Power Smarter Partnerships: Explore Co-development Models, Terms, and Dealmakers Across the Global Biopharma Landscape
The Co-development Deals in Pharmaceuticals and Biotechnology 2016–2026 report delivers the most comprehensive analysis of collaborative development agreements in the life sciences sector. Spanning nearly a decade of activity, the report provides a data-rich view into how companies co-develop drug candidates, share development risk, and align commercialization responsibilities.
This fully updated edition explores real-world co-development deals and includes financial terms, partnering strategies, and links to actual SEC-filed contract documents where available.
Free report sample
Key Features & Benefits
✔ Covers Deals from 2016 to 2026
Track the evolution of co-development dealmaking and identify strategic patterns.
✔ Analyze Deal Structures and Terms
Understand how co-development deals are structured—who contributes what, how risks are shared, and how profits are split.
✔ Benchmark Financials with Confidence
Review headline values, milestone payments, and equity contributions to support your own deal modeling.
✔ Access Real Contract Language
Where available, examine actual contract filings to gain insight into deal clauses, definitions, and triggers.
✔ Spot the Most Active Players
Identify the top 25 companies engaging in co-development deals—and learn what differentiates their approach.
What’s Inside – Chapter Breakdown
Chapter 1: Introduction
An overview of co-development dealmaking, why companies choose this model, and how this report is structured.
Chapter 2: Trends in Co-development Activity
Visual and narrative analysis of co-development deals by year, sector, therapeutic area, and region.
Chapter 3: Deal Structures & Key Clauses
Breaks down how companies share IP, development responsibilities, costs, and commercialization rights.
Chapter 4: High-Value Co-development Deals
Profiles of major deals sorted by disclosed value. Includes financial terms, strategic rationale, and links to original contracts where publicly available.
Chapter 5: Top 25 Active Co-development Dealmakers
Company profiles with deal histories and partnership approaches—including links to each company's full deal records.
Chapter 6: Comprehensive Deal Directory
Detailed index of co-development deals organized by:
-
Company A–Z
-
Therapy area
-
Technology type
-
Deal type
Each record links to the Current Agreements database, with contract documents where available.
Who Should Use This Report?
✅ Business Development & Licensing Professionals – Evaluate structures, terms, and partner roles across successful deals.
✅ C-Level Executives & Investors – Understand how collaborative development can accelerate product pipelines and reduce burn.
✅ Legal & Contract Managers – Benchmark real-world clauses and deal mechanics to guide your own term sheets.
✅ Commercial & Strategic Planners – Learn how rights, responsibilities, and revenues are allocated across co-development partners.
Why This Report Matters
As development costs rise and timelines tighten, co-development deals offer a compelling solution—shared risk, aligned incentives, and faster execution. This report helps you understand what’s market standard, what’s negotiable, and what leading companies are doing to succeed in shared R&D partnerships.
Learn from real deals. See how the leaders collaborate. Build stronger partnerships. Order your copy of Co-development Deals in Pharmaceuticals and Biotechnology today.
✔ Covers Deals from 2016 to 2026
Track the evolution of co-development dealmaking and identify strategic patterns.
✔ Analyze Deal Structures and Terms
Understand how co-development deals are structured—who contributes what, how risks are shared, and how profits are split.
✔ Benchmark Financials with Confidence
Review headline values, milestone payments, and equity contributions to support your own deal modeling.
✔ Access Real Contract Language
Where available, examine actual contract filings to gain insight into deal clauses, definitions, and triggers.
✔ Spot the Most Active Players
Identify the top 25 companies engaging in co-development deals—and learn what differentiates their approach.
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in co-development dealmaking
2.1. Introduction
2.2. Definition of co-development deal
2.3. Trends in co-development deals since 2016
2.3.1. Co-development dealmaking by year, 2016-2026
2.3.2. Co-development dealmaking by phase of development, 2016-2026
2.3.3. Co-development dealmaking by industry sector, 2016-2026
2.3.4. Co-development dealmaking by therapy area, 2016-2026
2.3.5. Co-development dealmaking by technology type, 2016-2026
2.3.6. Co-development dealmaking by most active company, 2016-2026
2.4. Reasons for entering into co-development partnering deals
2.5. The future of co-development deals
Chapter 3 – Overview of co-development deal structure
3.1. Introduction
3.2. Co-development agreement structure
Chapter 4 – Leading co-development deals
4.1. Introduction
4.2. Top co-development deals by value
Chapter 5 – Top 25 most active co-development dealmakers
5.1. Introduction
5.2. Top 25 most active co-development dealmakers
Chapter 6 – Co-development deals including contracts directory
6.1. Introduction
6.2. Co-development deals with contracts 2016-2026
Deal directory
Deal directory – co-development dealmaking by companies A-Z
Deal directory – co-development dealmaking by therapy area
Deal directory – co-development dealmaking by technology type
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering
TABLE OF FIGURES
Figure 1: Definition of co-development deal
Figure 2: Trends in co-development deal announcements, 2016-2026
Figure 3: Co-development deals signed at each phase of development, 2016-2026
Figure 4: Co-development deals by industry sector, 2016-2026
Figure 5: Co-development deals by therapy area, 2016-2026
Figure 6: Co-development deals by technology type, 2016-2026
Figure 7: Top 25 most active co-development dealmakers, 2016-2026
Figure 8: Top co-development deals by value, 2016-2026
Figure 9: Most active co-development dealmakers, 2016-2026
Pricing options
- $3,995: single-user (encrypted file - one user/device)
- $5,995: multi-user (encrypted file - up to 5 users/devices)
- $7,995: company (unencrypted file)
Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.
Company license files are not encrypted and can be accessed using a PDF Reader.
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Delivery Deadline
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Biopharma Research Ltd based in York, United Kingdom. We have been trading successfully online since 2012 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
A definitive, evidence-based approach to dealmaking intelligence
Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.
Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.
All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.
Our methodology
Built on a continuously updated proprietary database
All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.
Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.
Comprehensive and verifiable data sourcing
Deal data is sourced from publicly available industry disclosures, including:
-
Company press releases and announcements
-
SEC filings and equivalent regulatory disclosures
-
Company and investor presentations
-
Conference materials and company websites
All sources are captured and referenced, enabling full transparency and user verification.
Broad coverage across deal types and structures
Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:
-
Licensing and co-development
-
Research and collaborative R&D
-
Manufacturing, supply, and distribution
-
Commercialisation and co-promotion
-
Equity investments, joint ventures, and asset transactions
-
Options, royalties, and financing agreements
This breadth ensures a complete view of how partnerships are structured across the life sciences sector.
Structured, standardised analysis
Every deal is analysed using a consistent framework, capturing (where disclosed):
-
Financial terms — including upfront payments, milestones, and royalties
-
Rights allocation — development, manufacturing, and commercialization responsibilities
-
Deal structure — exclusivity, territorial scope, and agreement type
-
Contractual provisions — clauses defining risk, control, and value-sharing
Each deal record is fully categorised, including data fields such as:
-
Therapy area and technology type
-
Stage of development
-
Asset type and deal components
-
Geographic scope and exclusivity
-
Source documentation, including press releases and SEC filings
Financial normalisation for comparability
All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.
Contract-level insight
Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.
This enables users to understand:
-
How financial mechanisms are defined and triggered
-
How responsibilities are operationalised between parties
-
How flexibility, risk, and control are allocated within agreements
Designed for real-world application
Current Partnering reports are built to support business-critical decision-making, including:
-
Benchmarking comparable transactions
-
Supporting valuation and deal structuring
-
Preparing for negotiations
-
Evaluating potential partners
-
Informing internal strategy with real-world evidence
A trusted industry reference
With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies and emerging biotechs as a trusted source of dealmaking intelligence.
By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.
